Nuwellis Announces Appointment of Chief Financial Officer
19 October 2022 - 10:00PM
Continuing its commitment to expanding access to life-saving
ultrafiltration therapies for adult and pediatric patients
suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE) today
announced the appointment of Lynn Blake as Chief Financial Officer,
effective October 19, 2022.
“Nuwellis is entering our next phase of
commercial development with significant new opportunities in heart
failure, pediatrics and critical care. The deep knowledge and
experience in healthcare that Lynn brings will be instrumental as
we advance our mission of bringing our Aquadex SmartFlow®
technology to more patients,” said Nestor Jaramillo, Jr., President
and CEO of Nuwellis. “Lynn’s medical device industry experience,
combined with her strong financial leadership skills, makes her
uniquely qualified for the next phase of our journey. I'm excited
to welcome her to the team as we continue our dynamic growth."
Ms. Blake brings more than two decades of senior
financial leadership experience. Most recently, she served as a
Managing Director at Growth Operators Advisory Services. Prior to
that she served as Chief Financial Officer at Tactile Systems
Technology (“Tactile Medical”), where she led the company’s initial
public offering in 2016. Lynn has also served as Chief Financial
Officer of Taylor-Wharton International LLC and Analysts
International Corporation, in addition to holding prior leadership
positions at Entegris, Inc. and MTS Systems Corporation.
She holds an MBA from the University of
Minnesota and a B.S. from the University of Wisconsin-Madison.
“I believe Nuwellis not only has tremendous
market opportunity, but there is also something truly unique about
the way the company invests in the patients and healthcare
providers it serves,” said Lynn Blake, CFO of Nuwellis. “It’s an
exciting time to join Nuwellis. I’m eager to apply my financial
expertise in supporting the commercial organization as the company
seeks to broaden its therapeutic footprint and reach more patients
both domestically and abroad.”
About NuwellisNuwellis, Inc.
(Nasdaq: NUWE) is a medical device company dedicated to
transforming the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The Company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow® System for ultrafiltration therapy. Nuwellis is
headquartered in Minneapolis, MN, with a wholly owned subsidiary in
Ireland. The Company has been listed on the Nasdaq Capital Market
since February 2012.
About the Aquadex SmartFlow®
SystemThe Aquadex SmartFlow System delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow System is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a healthcare provider, within an
outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking
StatementsCertain statements in this release may be
considered forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the new market opportunities and
anticipated growth in 2021 and beyond. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risks associated with our ability to execute on
our commercialization strategy, the impact of the COVID-19
pandemic, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, our post-market
clinical data collection activities, benefits of our products to
patients, our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. Nuwellis does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
CONTACTS
INVESTORS:
Nestor Jaramillo, Jr.
President & CEO, Nuwellis, Inc.
ir@nuwellis.com
Vivian Cervantes
Gilmartin Group LLC
vivian.cervantes@gilmartinir.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Oct 2023 to Oct 2024